Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,074 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex.
Bussiere DE, Xie L, Srinivas H, Shu W, Burke A, Be C, Zhao J, Godbole A, King D, Karki RG, Hornak V, Xu F, Cobb J, Carte N, Frank AO, Frommlet A, Graff P, Knapp M, Fazal A, Okram B, Jiang S, Michellys PY, Beckwith R, Voshol H, Wiesmann C, Solomon JM, Paulk J. Bussiere DE, et al. Among authors: xu f. Nat Chem Biol. 2020 Jan;16(1):15-23. doi: 10.1038/s41589-019-0411-6. Epub 2019 Dec 9. Nat Chem Biol. 2020. PMID: 31819272
Author Correction: Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex.
Bussiere DE, Xie L, Srinivas H, Shu W, Burke A, Be C, Zhao J, Godbole A, King D, Karki RG, Hornak V, Xu F, Cobb J, Carte N, Frank AO, Frommlet A, Graff P, Knapp M, Fazal A, Okram B, Jiang S, Michellys PY, Beckwith R, Voshol H, Wiesmann C, Solomon JM, Paulk J. Bussiere DE, et al. Among authors: xu f. Nat Chem Biol. 2020 Mar;16(3):361. doi: 10.1038/s41589-020-0471-7. Nat Chem Biol. 2020. PMID: 31942047
A lipoprotein lipase-GPI-anchored high-density lipoprotein-binding protein 1 fusion lowers triglycerides in mice: Implications for managing familial chylomicronemia syndrome.
Nimonkar AV, Weldon S, Godbout K, Panza D, Hanrahan S, Cubbon R, Xu F, Trauger JW, Gao J, Voznesensky A. Nimonkar AV, et al. Among authors: xu f. J Biol Chem. 2020 Mar 6;295(10):2900-2912. doi: 10.1074/jbc.RA119.011079. Epub 2019 Oct 23. J Biol Chem. 2020. PMID: 31645434 Free PMC article.
Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies.
Lu H, Molony RD, Chen D, Jang S, Wolf B, Ewert S, Flaherty M, Xu F, Isim S, Shim Y, Dornelas C, Balke N, Leber XC, Scharenberg M, Koelln J, Choi E, Ward R, Johnson J, Calzascia T, Isnardi I, Williams JA, Lindenbergh PL, van de Donk NWCJ, Mutis T, Huet H, Lees E, Meyer MJ. Lu H, et al. Among authors: xu f. Mol Cancer Ther. 2020 Oct;19(10):2089-2104. doi: 10.1158/1535-7163.MCT-19-0003. Epub 2020 Aug 26. Mol Cancer Ther. 2020. PMID: 32847974
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy.
Sabatos-Peyton CA, Nevin J, Brock A, Venable JD, Tan DJ, Kassam N, Xu F, Taraszka J, Wesemann L, Pertel T, Acharya N, Klapholz M, Etminan Y, Jiang X, Huang YH, Blumberg RS, Kuchroo VK, Anderson AC. Sabatos-Peyton CA, et al. Among authors: xu f. Oncoimmunology. 2017 Nov 9;7(2):e1385690. doi: 10.1080/2162402X.2017.1385690. eCollection 2018. Oncoimmunology. 2017. PMID: 29308307 Free PMC article.
Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Schwartz S, Patel N, Longmire T, Jayaraman P, Jiang X, Lu H, Baker L, Velez J, Ramesh R, Wavreille AS, Verneret M, Fan H, Hu T, Xu F, Taraszka J, Pelletier M, Miyashiro J, Rinne M, Dranoff G, Sabatos-Peyton C, Cremasco V. Schwartz S, et al. Among authors: xu f. Immunother Adv. 2022 Aug 10;2(1):ltac019. doi: 10.1093/immadv/ltac019. eCollection 2022. Immunother Adv. 2022. PMID: 36196369 Free PMC article.
14,074 results
You have reached the last available page of results. Please see the User Guide for more information.